US 7,541,438 B2
	Monoclonal antibody against connective tissue growth factor and medicinal uses thereof
Takuya Tamatani, Kanagawa (Japan); Katsunari Tezuka, Kanagawa (Japan); Shinji Sakamoto, Kanagawa (Japan); and Masaharu Takigawa, Okayama (Japan)
Assigned to Amgen, Inc., Thousand Oaks, Calif. (US)
Filed on Jan. 04, 2006, as Appl. No. 11/324,769.
Application 10/390986 is a division of application No. 09/582337, granted, now 6,562,618, previously published as PCT/JP98/05697, filed on Dec. 16, 1998.
Application 11/324769 is a continuation of application No. 10/390986, filed on Mar. 17, 2003, abandoned.
Claims priority of application No. 9-367699 (JP), filed on Dec. 25, 1997; and application No. 10-356183 (JP), filed on Dec. 15, 1998.
Prior Publication US 2006/0223133 A1, Oct. 05, 2006
Int. Cl. C07K 16/00 (2006.01); C12P 21/08 (2006.01); C12N 5/00 (2006.01); C12N 5/06 (2006.01); C07K 17/00 (2006.01)

U.S. Cl. 530—387.1  [530/387.3; 530/388.1; 530/388.15; 530/388.23; 435/325; 435/326; 435/328; 435/335]

35 Claims

1. A human monoclonal antibody which specifically binds to full-length human connective tissue growth factor (CTGF), or antigen binding portion thereof, wherein said human monoclonal antibody is produced by a hybridoma identified by an international deposit accession No. FERM BP-6535.